Drugs / CBD
last change Jul 2025 re-read 2 minutes ago

CBD

Developed for
type 2 diabetes mellitus
Investigated by
Lexaria Bioscience Corp.

Trials 1 · a red edge is where a trial was stopped

20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06648031 Dec 2024 → Jul 2025 type 2 diabetes mellitus Lexaria Bioscience Corp. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CBD ClinicalTrials.gov intervention name — accepted as the source's own label NCT06648031
Route Oral “Route of administration: OralNCT06648031